What Denali Therapeutics does

Denali Therapeutics is a clinical-stage and now commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier to treat neurodegenerative diseases and lysosomal storage disorders. The company's proprietary TransportVehicle (TV) platform is a modular delivery technology using Transferrin Receptor targeting to deliver large molecule biotherapeutics — including enzymes, oligonucleotides, and antibodies — to the brain following systemic administration, achieving 10-30x greater brain exposure than conventional methods. In March 2026, the FDA granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier, for the treatment of neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. The company's pipeline extends the TV platform across multiple franchises, including DNL126 (Sanfilippo syndrome type A), DNL952 (Pompe disease), DNL593 (frontotemporal dementia), and DNL628 (Alzheimer's disease).

Denali's business model centers on commercial sales of AVLAYAH priced at $5,200 per 150mg vial with annual treatment costs of $270,000-$811,000 depending on patient weight — a ~60% premium over the Elaprase standard of care. The company targets an addressable population of approximately 400-500 US patients and ~2,000 globally, distributed through specialty pharmacies with patient support services. Non-dilutive capital sources include a $275M synthetic royalty agreement with Royalty Pharma (9.25% royalty on worldwide net sales) and a $195M sale of a Rare Pediatric Disease Priority Review Voucher. Equity financing has included a $500M private placement in February 2024 and a $200M public offering in December 2025, bringing cash and equivalents to approximately $1.05-1.17 billion.

Denali is headquartered in South San Francisco, California, with additional offices in Salt Lake City, Utah (manufacturing) and Zurich, Switzerland. The company is publicly traded on NASDAQ under the ticker DNLI with a market capitalization of approximately $4.05 billion as of June 2026, 251-500 employees, and 92.92% institutional ownership. Recent strategic setbacks include the discontinuation of BIIB122 with Biogen after the Phase 2b LUMA trial failed in idiopathic Parkinson's disease, and the termination of the DNL593 collaboration by Takeda, both of which have refocused the company on independent pipeline development.

Name

Denali Therapeutics

Legal name

Denali Therapeutics Inc.

Website

https://denalitherapeutics.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

Denali Therapeutics is a commercial-stage biopharmaceutical company developing therapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform, serving patients with neurodegenerative diseases and lysosomal storage disorders such as Hunter syndrome.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Neurodegenerative and Rare Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology/CNS Gene Therapies (HLAAACAH), Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Blood-brain barrier delivery
• Enzyme replacement therapy
• Neurodegenerative disease therapeutics
• Lysosomal storage disorder treatment
• Biotherapeutic drug development

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AVLAYAH Product Sales: Revenue from commercial sales of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome. Priced at $5,200 per 150mg vial with annual costs of $270,000-$811,000 depending on patient weight. Targeting approximately 400-500 US patients and ~2,000 globally.
2. Royalty Revenue: Non-dilutive royalty funding arrangement with Royalty Pharma providing $275 million based on future net sales of tividenofusp alfa, with Royalty Pharma receiving 9.25% royalty on worldwide net sales
3. Priority Review Voucher Sale: Sale of FDA Rare Pediatric Disease Priority Review Voucher earned from AVLAYAH approval for $195 million in June 2025

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Denali Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes biotherapeutics capable of crossing the blood-brain barrier. Its FDA-approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients, launched in March 2026 as the first FDA-approved biologic designed to cross the BBB. The company also maintains a clinical pipeline spanning Sanfilippo syndrome type A, Pompe disease, frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, all built on its proprietary TransportVehicle (TV) platform.

Product overview

Denali Therapeutics is a biopharmaceutical company that has transitioned from R&D to commercial-stage operations with the FDA approval of AVLAYAH in March 2026. The company's core offering centers on its proprietary TransportVehicle (TV) platform, which enables biotherapeutics to cross the blood-brain barrier. The TV platform supports three franchise areas: Enzyme TransportVehicle (ETV) for lysosomal storage disorders, Oligonucleotide TransportVehicle (OTV) for CNS gene expression modulation, and Antibody TransportVehicle (ATV) for antibody delivery to the brain. The approved product AVLAYAH (tividenofusp alfa-eknm) is an enzyme replacement therapy for Hunter syndrome. The pipeline includes multiple candidates across lysosomal storage disorders, neurodegenerative diseases, and inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Brands

• TransportVehicle™ (TV) Platform: Proprietary platform enabling delivery of enzymes, oligonucleotides and antibodies across the blood-brain barrier
• Enzyme TransportVehicle™ (ETV)
• Oligonucleotide TransportVehicle™ (OTV)
• Antibody TransportVehicle™ (ATV)
• AVLAYAH™ (tividenofusp alfa-eknm)

Products and services

• AVLAYAH (tividenofusp alfa-eknm) FDA-approved enzyme replacement therapy for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. AVLAYAH uses Denali's proprietary TransportVehicle technology to cross the blood-brain barrier, addressing CNS symptoms that previous enzyme replacement therapies like Elaprase cannot treat. Priced at $5,200 per 150mg vial with annual costs of $270,000–$811,000 depending on patient weight.

Quantifiable outcome

• 91% reduction in cerebrospinal fluid heparan sulfate levels after 24 weeks of treatment with AVLAYAH
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• BiogencoreStrategic or Co-development Partner · 1 March 2020Partnership formed in 2020 with approximately $400 million total potential value for co-development and co-commercialization of BIIB122 (DNL151), an LRRK2 inhibitor for Parkinson's disease. The collaboration included upfront payment and potential milestones. In May 2026, the companies discontinued development of BIIB122 for idiopathic Parkinson's after Phase 2b LUMA trial failure, though Denali continues independent Phase 2a BEACON trial for LRRK2-associated Parkinson's.
• TakedacoreStrategic or Co-development Partner · 1 January 2018Collaboration established in 2018 for co-development of neurodegenerative disease treatments including DNL593 (progranulin replacement therapy for frontotemporal dementia). Takeda terminated the partnership in April 2026 for strategic reasons unrelated to efficacy or safety, returning full rights to Denali. Phase 1/2 study results expected by end of 2026.
• SanofiminorStrategic or Co-development Partner · 1 January 2018Partnership to develop RIPK1 inhibitors for conditions including Alzheimer's, ALS, and Multiple Sclerosis. Sanofi effectively ended the collaboration in January 2026 by deprioritizing eclitasertib, with Denali also having dropped its RIPK1 program earlier.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sarepta Therapeutics: Sarepta develops genetic medicines including gene therapies and antisense oligonucleotides for rare diseases, with a focus on Duchenne muscular dystrophy and other genetic neuromuscular conditions. Sarepta directly competes with Denali in the platform-based genetic medicine space for rare CNS and neuromuscular disorders.
• Sage Therapeutics: Sage Therapeutics is a CNS specialty pharmaceutical company developing treatments for neurological conditions including postpartum depression (Zurzuvae) and epileptic encephalopathies. Sage directly competes with Denali in the CNS specialty pharma space with a similar focus on rare neurological indications.
• Voyager Therapeutics: Voyager Therapeutics develops gene therapies for CNS diseases using AAV vectors, with a particular focus on improving brain delivery of genetic medicines — directly overlapping with Denali's mission of delivering therapeutics across the BBB. Voyager represents a competing approach (viral vectors vs. transferrin receptor) to the same fundamental problem.
• BioMarin Pharmaceutical: BioMarin is a direct peer as a rare disease-focused biotech with a portfolio of enzyme replacement and biologic therapies for lysosomal storage disorders and other genetic conditions. Both companies develop biologic therapies for small patient populations in genetic diseases, with comparable premium orphan drug pricing models and similar regulatory pathways.
• Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide (ASO) therapeutics company, developing treatments for neurological and rare diseases including SMA (Spinraza), ALS, and Huntington's. Ionis directly competes with Denali's OTV platform franchise, which uses oligonucleotides to modulate CNS gene expression, and shares the same mechanism class for many pipeline programs.
• Wave Life Sciences: Wave Life Sciences is a direct peer developing stereopure antisense oligonucleotides for CNS diseases including Huntington's, ALS, and Duchenne muscular dystrophy. Wave directly competes with Denali's OTV platform in the ASO-for-CNS space and shares a similar focus on neurological genetic diseases.

Emerging players

• REGENXBIO: REGENXBIO is a gene therapy company developing AAV-based treatments including for CNS indications, with proprietary NAV technology platform. REGENXBIO's AAV delivery approach directly competes with Denali's transferrin receptor BBB-crossing platform as alternative routes to brain delivery of genetic medicines.
• uniQure: uniQure is a gene therapy company developing AAV-based treatments for CNS and other rare diseases, including Huntington's disease. uniQure represents an alternative platform approach to delivering genetic medicines to the brain, overlapping with Denali's CNS gene therapy ambitions.

Broad incumbents

• Eli Lilly: Eli Lilly is a broad incumbent in neurodegenerative and rare disease therapeutics, with major programs in Alzheimer's (Kisunla), Parkinson's, and rare diseases. Lilly's neuroscience franchise competes with Denali at the indication level (Alzheimer's, Parkinson's) despite operating at vastly larger scale and not specializing in BBB delivery.
• Biogen: Biogen is a broad incumbent in CNS therapeutics with established franchises in multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer's (Aduhelm/Leqembi), and was a major Denali partner on BIIB122 for Parkinson's. Biogen operates at much larger scale across many CNS indications rather than specializing in BBB delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/denali-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Denali Therapeutics